Skip to main content
Journal for Immunotherapy of Cancer logoLink to Journal for Immunotherapy of Cancer
. 2020 Jun 21;8(1):e000798corr1. doi: 10.1136/jitc-2020-000798corr1

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

PMCID: PMC7307533  PMID: 32571997

Xie L, Xu J, Sun X, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer 2020;8:e000798. doi: 10.1136/jitc-2020-000798.

Since the online publication of this article, the authors have noticed that in figure 4 the dotted and full lines were mislabelled. Please see the corrected Figure below:

Figure 4.

Figure 4


Articles from Journal for Immunotherapy of Cancer are provided here courtesy of BMJ Publishing Group

RESOURCES